Showing 5351-5360 of 5956 results for "".
- Occupational Radiation Exposure Tied to Higher Cataract Riskhttps://modernod.com/news/occupational-radiation-exposure-tied-to-higher-cataract-risk/2477191/Higher cumulative occupational exposure to low-dose radiation is associated with excess additive risk (EAR) of developing cataract, according to a new study in a large prospective cohort of U.S. radiation technologists, Reuters reported. <
- Bausch Health Licenses Novaliq’s NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunctionhttps://modernod.com/news/bausch-health-licenses-novaliqs-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2477185/Bausch Health Companies and Novaliq have announced that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexy
- Midwest Vision Partners Announces Partnership With Cleveland Eye Clinichttps://modernod.com/news/midwest-vision-partners-announces-partnership-with-cleveland-eye-clinic/2477186/Eye care management company Midwest Vision Partners (MVP) has announced its partnership with Cleveland Eye Clinic (CEC). Terms of the deal were not disclosed. MVP’s partnership with CEC expands its network to 19 locations in Ohio with 33 physicians providing medical and surgic
- Trump Administration Advances Plan to Allow Certain Prescription Drug Imports From Canadahttps://modernod.com/news/trump-administration-advances-plan-to-allow-certain-prescription-drug-imports-from-canada/2477183/The US Department of Health and Human Services (HHS) said the Trump administration is pushing ahead with a plan to allow certain prescription drugs to be imported from Canada. “For the first time in history HHS and FDA are open to importation as a means for lower prices,” co
- ProtoKinetix AAGP Retinal Cell Replacement Therapy Testing at UBC Completedhttps://modernod.com/news/protokinetix-aagp-retinal-cell-replacement-therapy-testing-at-ubc-completed/2477184/ProtoKinetix announced the completion of an in vivo study to assess the effect of AAGP on the long term survival and functional activity of photoreceptor precursor cells (PPCs) in the animal ocular model of genetic retinal degeneration. The objective of this study was to determine t
- Staar Surgical Announces Strategic Alliance Agreement with California Center for Refractive Surgery (CCRS)https://modernod.com/news/staar-surgical-announces-strategic-alliance-agreement-with-california-center-for-refractive-surgery-ccrs/2477178/Staar Surgical announced it has entered into a strategic alliance with the California Center for Refractive Surgery (CCRS), a Los Angeles based eye care group with locations in Hancock Park and Sherman Oaks. “Our new multi-clinic alliance with CCRS and its founder Dr. Paul Lee is represent
- 1-800 Contacts Enters Agreement to Acquire Vision Start-Up 6over6 Visionhttps://modernod.com/news/1-800-contacts-enters-agreement-to-acquire-vision-start-up-6over6-vision/2477177/1-800 Contacts announced that it entered into a definitive agreement to acquire 6over6 Vision (6over6), a provider of at-home vision tests using a mobile app or computer. Terms of the deal were not disclosed. 6over6 currently offers a vari
- FFL Partners To Sell EyeCare Partners to Partners Group Holdinghttps://modernod.com/news/ffl-partners-to-sell-eyecare-partners/2477173/Private Equity Firm FFL Partners has has signed a definitive agreement to sell EyeCare Partners (ECP), the largest medically focused and integrated eye care services provider in the US, to Partners Group Holding. While financial terms of the deal were not disclosed, The Wall Street Jou
- FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)https://modernod.com/news/fda-advisory-committee-votes-unanimously-to-support-the-use-of-teprotumumab-for-the-treatment-of-thyroid-eye-disease-ted/2477171/Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the FDA voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal antibody (mAb), outweigh the potential risks for the treatment of Thyroid Eye Disease (TED).
- Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMDhttps://modernod.com/news/novartis-receives-positive-chmp-opinion-for-beovu-brolucizumab-for-the-treatment-of-wet-amd/2477172/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).<